Impact of hypofractionated radiotherapy on 3D breast cancer models
Source abstract
Abstract
A hypofractionated radiation therapy (RT) regimen delivering 5.2 Gy per fraction (total 26 Gy) is safe and effective, providing breast cancer (BCa) control for up to five years. However, there is limited knowledge about cellular responses to hypofractionated RT using relevant preclinical models. In this study, three-dimensional (3D) gelatin methacryloyl (GelMA) hydrogels were utilized to examine BCa cell response to hypofractionated RT. Herein, 3D cultures of MCF-7 and MDA-MB-231 cell lines and patient-derived BCa cells were subjected to hypofractionated RT and grown over 70 days in GelMA hydrogels. To assess the cellular response, we analyzed metabolic activity, DNA damage, cell viability and molecular markers of cancer stem cells (CSCs). Cell viability and metabolic activity declined following RT in both BCa cell lines and patient-derived cells. RT significantly increased CSC marker ALDH1A1 by day 35. Post-RT, CSC subpopulations secreted IL-8, potentially associated with an increase in tumor aggressiveness. This study demonstrates BCa cell responses to hypofractionated RT and highlights GelMA as a valuable preclinical RT model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Radiotherapy Techniques · Breast Cancer Treatment Studies · MRI in cancer diagnosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (87)
Show source-provided references
1. Use of conventional radiation therapy as part of breast-conserving treatment10.1200/JCO.2005.11.018 ↗
2. Once-daily radiation therapy for inflammatory breast cancer10.1016/j.ijrobp.2014.01.054 ↗
3. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France10.1200/JCO.1997.15.3.963 ↗
4. Efficacy of 8 Gy single fraction palliative radiation therapy in painful bone metastases: a single institution experience
5. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer10.1016/0360-3016(92)90895-O ↗
6. The role of the radiation therapy breast boost in the 2020s10.1016/j.breast.2023.03.009 ↗
7. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-Year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial10.1016/S0140-6736(20)30932-6 ↗
8. Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients10.1186/s12885-024-11918-2 ↗
9. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward trial10.1016/j.radonc.2016.02.027 ↗
10. Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands
11. GelMA, click-chemistry gelatin and bioprinted polyethylene glycol-based hydrogels as 3D Ex vivo drug testing platforms for patient-derived breast cancer organoids10.3390/pharmaceutics15010261 ↗
12. A method for prostate and breast cancer cell spheroid cultures using gelatin methacryloyl-based hydrogels10.1007/978-1-4939-7845-8_10 ↗
13. Generation of three-dimensional (3d) breast cancer bone metastasis model for drug testing10.22203/eCM.v052a04 ↗
14. The DNA damage response: implications for tumor responses to radiation and chemotherapy10.1146/annurev-med-081313-121208 ↗
15. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer10.1038/s41392-020-0150-x ↗
16. Radiation-induced signaling pathways that promote cancer cell survival (review)10.3892/ijo.2014.2614 ↗
17. Artemis links ATM to double strand break rejoining10.4161/cc.4.3.1527 ↗
18. SDC4-rs1981429 and ATM-rs228590 May provide early biomarkers of breast cancer risk10.1007/s00432-022-04236-2 ↗
19. Double-strand DNA break repair: molecular mechanisms and therapeutic targets10.1002/mco2.388 ↗
20. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX10.1074/jbc.M109.078436 ↗
21. Nuclear localization of p38 MAPK in response to DNA damage10.7150/ijbs.5.428 ↗
22. Cytokine profile of breast cell lines after different radiation doses10.1080/09553002.2017.1362504 ↗
23. Inflammation and cancer: back to Virchow?10.1016/S0140-6736(00)04046-0 ↗
24. Nucleic acid/cyanine composite nanomedicine for targeted remote tumor therapy to counteract RT-induced immunosuppression10.1016/j.mattod.2025.06.036 ↗
25. Efficient killing of radioresistant breast cancer cells by cytokine-induced killer cells10.1177/1010428317695961 ↗
26. Crosstalk of inflammatory cytokines within the breast tumor microenvironment10.3390/ijms24044002 ↗
27. Cytokines and immune response in the tumor microenvironment10.1097/00002371-200109000-00002 ↗
28. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 13910.1074/jbc.273.10.5858 ↗
29. Prediction of radiation sensitivity using a gene expression classifier10.1158/0008-5472.CAN-05-0656 ↗
30. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT510.1111/cas.13776 ↗
31. Transcription factor c-Jun activation represses mdr-1 gene expression
32. Non-classical notch signaling by MDA-MB-231 breast cancer cell-derived small extracellular vesicles promotes malignancy in poorly invasive MCF-7 cells10.1038/s41417-021-00411-8 ↗
33. Moving forward fast with FAST-Forward10.1016/j.clon.2021.04.007 ↗
34. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-Year follow-up results of two randomised controlled trials10.1016/S1470-2045(13)70386-3 ↗
35. Is FAST FORWARD the way forward in radiotherapy for locally advanced breast cancer - learnings from the COVID pandemic10.1016/j.clbc.2023.11.003 ↗
36. Radiotherapy resistance of 3D bioprinted glioma via ITGA2/p-AKT signaling pathway10.1002/adhm.202303394 ↗
37. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer10.3892/or.2015.3767 ↗
38. Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response10.2174/1381612824666180404152304 ↗
39. The extracellular matrix as a cell survival factor10.1091/mbc.4.9.953 ↗
40. Cancer nucleus: morphology and beyond10.1002/dc.21234 ↗
41. Interphase nucleolar organizer regions in cancer cells10.1016/B978-0-12-364932-4.50008-3 ↗
42. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues10.1002/(SICI)1096-9896(200006)191:2<181::AID-PATH607>3.0.CO;2-V ↗
43. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy10.1074/jbc.M310030200 ↗
44. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy
45. Persistent gammaH2AX: a promising molecular marker of DNA damage and aging10.1016/j.mrrev.2015.07.001 ↗
46. Modulation of Huh7.5 spheroid formation and functionality using modified PEG-Based hydrogels of different stiffness10.1371/journal.pone.0118123 ↗
47. Hyperbaric oxygen therapy for malignancy: a review10.1007/s00268-006-0190-6 ↗
48. Spheroids and cell survival10.1016/S1040-8428(00)00077-9 ↗
49. Matrix stiffness induces a tumorigenic phenotype in mammary epithelium through changes in chromatin accessibility10.1038/s41551-019-0420-5 ↗
50. 3D environment favors persistent changes in cell functions and altered morphology, wrinkling, and biomechanical signature of the nucleus
51. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough
52. Detecting heterogeneity in and between breast cancer cell lines10.1186/s41236-020-0010-1 ↗
53. Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: lumican a key regulator
54. Filopodia in cell adhesion, 3D migration and cancer cell invasion10.1016/j.ceb.2015.06.007 ↗
55. Regulation of cancer cell metabolism10.1038/nrc2981 ↗
56. Dormancy in cancer10.1111/cas.13917 ↗
57. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis10.2147/OTT.S140854 ↗
58. Mechanisms of cancer cell Dormancy--Another hallmark of cancer?10.1158/0008-5472.CAN-15-1370 ↗
59. Cancer dormancy: a model of early dissemination and late cancer recurrence10.1158/1078-0432.CCR-11-2186 ↗
60. The Ku heterodimer: function in DNA repair and beyond10.1016/j.mrrev.2014.06.002 ↗
61. DNA ligase IV-deficient cells are more resistant to ionizing radiation in the absence of Ku70: implications for DNA double-strand break repair10.1073/pnas.201271098 ↗
62. The DNA damage response during mitosis
63. Insight into the architecture of the NuRD complex: structure of the RbAp48-MTA1 subcomplex10.1074/jbc.M114.558940 ↗
64. Radiation-inducible protein RbAp48 contributes to radiosensitivity of cervical cancer cells10.1016/j.ygyno.2013.06.002 ↗
65. Androgen receptor signaling regulates DNA repair in prostate cancers10.1158/2159-8290.CD-13-0172 ↗
66. Genomic analysis of DNA repair genes and androgen signaling in prostate cancer10.1186/s12885-018-4848-x ↗
67. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells10.1186/1476-4598-13-52 ↗
68. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells10.1038/sj.onc.1207147 ↗
69. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses10.1038/cddis.2013.9 ↗
70. Chromatin remodeling--a novel strategy to control excessive alcohol drinking10.1038/tp.2013.4 ↗
71. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent10.1016/j.biocel.2007.02.009 ↗
72. Notch signaling enhances stemness by regulating metabolic pathways through modifying p53, NF-kappaB, and HIF-1alpha10.1089/scd.2017.0260 ↗
73. Epidermal notch signalling: differentiation, cancer and adhesion10.1016/j.ceb.2008.01.010 ↗
74. Role of CD44 in breast cancer10.3233/BD-190409 ↗
75. Profiling of gene expression associated with stemness and aggressiveness of ALDH1A1-Expressing human breast cancer cells10.21315/mjms2019.26.5.4 ↗
76. ALDH1A1 as a marker for metastasis initiating cells: a mechanistic insight10.1016/j.yexcr.2024.114213 ↗
77. ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2(-/-) ovarian cancer cells10.1158/1535-7163.MCT-19-0242 ↗
78. The biology and role of CD44 in cancer progression: therapeutic implications10.1186/s13045-018-0605-5 ↗
79. Multiplexed immunoassay-based serum cytokine profiling for potential prognosis predictors in patients with metastatic breast cancer10.21037/tcr.2018.11.29 ↗
80. TNF-Alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma10.1038/cgt.2008.62 ↗
81. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis10.1038/onc.2012.417 ↗
82. Serum Caspase-3 and Caspase-7 as predictive factors of response in locally advanced and metastatic breast carcinoma10.4236/jct.2014.56067 ↗
83. Cold exposure therapy sensitizes nanodrug-mediated radioimmunotherapy of breast cancer10.1021/acsnano.4c09021 ↗
84. Hilmi · 2024
85. Photo-Cross-Linkable, injectable, and highly adhesive GelMA-Glycol chitosan hydrogels for cartilage repair10.1002/adhm.202302078 ↗
86. Syndecan-1 and -4 influence wnt signaling and cell migration in human breast cancers10.1016/j.biochi.2022.01.014 ↗
87. Heparan sulfate proteoglycans as potential markers for in vitro human neural lineage specification10.3390/cells14151158 ↗